EP1066265A1 — Pyridazinone hydrochloride compound and method for producing the same
Assigned to Nissan Chemical Corp · Expires 2001-01-10 · 25y expired
What this patent protects
The present invention relates to a 3/2-hydrochloride of 4-chloro-5-[3- (4-benzylpiperazin-1- yl)carbonylmethoxy-4- methoxybenzylamino]- 3(2H)-pyridazinone, and also relates to a method for producing the 3/2- hydrochloride of 4-chloro-5-[3- (4-benzylpiperazin-1- yl)carbonylmethoxy…
USPTO Abstract
The present invention relates to a 3/2-hydrochloride of 4-chloro-5-[3- (4-benzylpiperazin-1- yl)carbonylmethoxy-4- methoxybenzylamino]- 3(2H)-pyridazinone, and also relates to a method for producing the 3/2- hydrochloride of 4-chloro-5-[3- (4-benzylpiperazin-1- yl)carbonylmethoxy-4- methoxybenzylamino]- 3(2H)-pyridazinone which comprises crystallizing in an alcohol type solvent or an alcohol type-ester type mixture solvent in the presence of hydrogen chloride and water.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.